Non-alcoholic fatty liver disease
Conditions
Interventions
Gold Standard:The pathological diagnosis is based on the gold standard.
Non alcoholic fatty liver disease (NAFLD): Fatty changes characterized by large or predominantly large follicles involving more
The combination of significant liver fibrosis or interstitial fibrosis (F2-3) is fibrotic NASH.
NAFLD related cirrhosis: Concomitant cirrhosis (F4) is NASH cirrhosis.
Index test:Expression of BCAR3, USP11, METTL3, and TRAF3.
Sponsors
The Fifth Affiliated Hospital of Southern Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: ? Voluntary signing of informed consent form; ? Age = 18 years old, = 60 years old; ? According to the judgment of the treating physician, patients who require liver and gallbladder surgery due to non fatty liver diseases are required to have a volume of at least 2 * 2 * 2cm of discarded liver tissue samples available for this experiment after surgery. ? Selection criteria for the experimental group: Patients diagnosed with NAFLD according to the AASLD Practice Guidance on the Clinical Assessment and Management of Nonalcoholic Fatty Liver Disease, 2023 Edition, and Expert Recommendations for Standardized Diagnosis and Treatment of Fatty Liver Disease (Revised 2019 Edition), who have been confirmed to have fatty liver by postoperative pathology, will be included in the experimental group. ? Selection criteria for the control group: Patients confirmed by postoperative pathology to have no fatty liver were included in the control group.
Exclusion criteria
Exclusion criteria: ? Lack of necessary demographic indicators, physical measurement indicators, laboratory indicators, etc. ? Lack of necessary past and medication history. ? History of drinking alcohol or excessive alcohol consumption: Over the past 12 months, the standard weekly alcohol consumption for males was 21 cups per week, while for females it was 14 cups per week. ? Apply drugs such as amiodarone, methotrexate, tamoxifen, and glucocorticoids. ? Specific diseases that can lead to fatty liver include genotype 3 hepatitis C virus infection, hepatolenticular degeneration, autoimmune hepatitis, total parenteral nutrition, beta lipoproteinemia, congenital lipid atrophy, celiac disease, etc. ? Patients with concomitant viral hepatitis, tumors, or other serious systemic diseases. ? Individuals with limited or no capacity for civil conduct. ? Pregnant patients.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Recombinant Breast Cancer Anti-Estrogen Resistance 3;Methyltransferase-like protein 3;ubiquitin specific peptidase 11;TNF receptor-associated factor 3; | — |
Countries
China
Contacts
Public ContactZhi Zhang
The Fifth Affiliated Hospital of Southern Medical University
Outcome results
None listed